About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT01500863

Endometrial Receptivity After GnRH Agonist Triggering

Conventional luteal phase support after human chorionic gonadotrophin (hCG) triggering in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) provides adequate pregnanc...

Lead sponsor: IVI Madrid•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

IVI Madrid

Age

18 - 35 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy oocyte donor women
•Aged 18-35 years
•With a menstrual cycle length of 26-35 days
•Normal ultrasound scan of uterus and ovaries
•Normal basal hormones
•No contraindication for controlled ovarian stimulation (COS)
•Willing to participate in the study and providing written informed consent.

Exclusion Criteria

•Subjects with current or previous history of an endocrine abnormality
•Subjects with an abnormal outcome of blood biochemistry or hematology
•Subjects with an abnormal cervical smear
•Subjects with a chronic disease
•Subjects with any relevant ovarian-, tubal- or uterine-pathology that could interfere with the COS treatment
•Pregnancy
•Subjects who had a previous history of ovarian hyperresponse or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral follicle count (AFC) of more than 20 on ultrasound (11 mm, both ovaries combined) .
•Previous low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to insufficient ovarian response or less than 6 oocytes obtained).
•A history of recurrent miscarriage,
•Smoking more than 10 cigarettes per day.
•Not willing to comply with study procedures

Related studies

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

NCT05588635 · Ovarian Hyperstimulation Syndrome, Frozen-thawed Embryo Transfers

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

NCT05198128 · Ovarian Hyperstimulation Syndrome

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

NCT04797338 · Pregnancy Early, Miscarriage, and more

COMPLETEDPhase 2

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

NCT04351126 · Ovarian Hyperstimulation Syndrome

TERMINATEDPhase 4

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709 · Endometrial Receptivity, Ovarian Hyperstimulation Syndrome

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 26, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment35

Start dateNov 2011

Last updatedOct 26, 2016

Condition

Ovarian Hyperstimulation Syndrome

Locations shown

Instituto Valenciano de Infertilidad

Madrid, Madrid

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 26, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions